Multiple Sclerosis Market Analysis & Forecasts Report 2007-2022

Table of Contents

Executive Summary

• Chart E1 Demographics of MS across Seven Major Markets
• Chart E2 Avonex Revenues ($m) across seven major markets, 2006
• Chart E3 Copaxone Revenues ($m) across six major markets, 2006
• Chart E4 Rebif Revenues ($m) across six major markets, 2006
• Chart E5 Betaseron/Betaferon Revenues ($m) across seven major markets, 2006
• Chart E6 Novantrone Revenues ($m) across seven major markets, 2006
• Chart E7 Tysabri Revenues ($m) in US and Germany, 2006
• Table E1 MS Revenue Forecast for Seven Major Markets, 2007-2012
• Chart E8 MS Revenue Forecast for Seven Major Markets, 2007-2012
• Table E2MS Revenue Forecast for Other Markets 2007-2012
• Chart E9 MS Revenue Forecast for Other Markets 2007-2012

Chapter 1. Introduction to Multiple Sclerosis (MS)

• 1.1Introduction

Chapter 2. Defining Multiple Sclerosis

• 2.1.1 Benign MS
• 2.1.2 Relapse-remitting MS
• 2.1.3 Primary progressive MS
• 2.1.4 Secondary progressive
• 2.1.5 Progressive relapsing MS
• 2.2 Symptoms and Differential Diagnosis
  • 2.2.1 Primary symptoms
  • 2.2.2 Secondary symptoms
  • 2.2.3 Tertiary symptoms
  • 2.2.4 Diagnosis of MS
• 2.3 The Risk factors of MS
  • 2.3.1 Immunologic Factors
  • 2.3.2 Environmental Effects may influence MS Incidence
  • 2.3.3 The Viral Induction of MS is possible
  • 2.3.4 The Genetic Basis of MS Exists
  • 2.3.5 Hormones Predispose Women to MS
• 2.4 The Demographics of MS
• Chart 2.1 Demographics of MS across Seven Major Markets

Chapter 3. Pharmaceutical Products for MS Treatment

• 3.1Current Pharmaceutical Drug Therapies
• Table 3.1. The Major Drug Treatments of MS
• 3.2 Relapsing-Remitting MS
  • 3.2.1 Avonex (Interferon beta 1a) to Reduce Severity of MS
  • 3.2.2 Rebif (Interferon beta 1a)
  • 3.2.3 Betaseron (Interferon beta 1b)
  • 3.2.4 Copaxone (Glatiramer acetate)
• 3.4 Antineoplastic Drugs (Relapse-Remitting & Secondary progressive)
  • 3.4.1 Cancer Drug, Novantrone (Mixonatrone) Benefits MS Sufferers
  • 3.4.2 Taxanes
    • 3.4.2.1 Taxol (paclitaxel)
  • 3.4.3 Immunosuppressants - Secondary Progressive and Worsening Relapse-Remitting MS
    • 3.4.3.1 Imuran (Azathioprine)
    • 3.4.3.2 Sandimmune (Cyclosporine)
• 3.5 Corticosteroids

Chapter 4. Leading Companies behind MS Therapy

• 4.1 Key Companies delivering MS Therapy
  • 4.1.1 Biogen Idec and Elan Pharmeceuticals
  • 4.1.2Merck Serono
  • 4.1.3 Bayer-Schering Pharmaceuticals' Betaseron
  • 4.1.4 Teva and Sanofi Aventis

Chapter 5. Oral MS Pharmaceuticals Research and Development (R&D)

• 5.1 Oral Market Industry
• Table 5.1. Factors influencing oral delivery of pharmaceutical products
  • 5.1.1 Oral drugs development for MS
  • 5.1.2 Leading companies in Oral delivery of MS therapeutics
    • 5.1.2.1 Biogen Idec and UCB
    • 5.1.2.2 Teva' s Laquinomod
    • 5.1.2.3 Serono' s Mylinax oral formulation given fast tract
    • 5.1.2.4 Novartis' s Fingolimod (FTY720)
    • 5.1.2.5 Sanofi-Aventis' s Teriflunomide set to file
    • 5.1.2.6 GW Sativex Investigational Cannabis-Based Treatment for MS
    • 5.1.2.7 Pfizer' s Lipitor (atorvastin) May See Extension through MS
• 5.2. Progressive forms of MS studies underway
  • 5.2.1Biogen Idec and Genentech to deliver MS therapeutics through Monoclonal Antibodies (Mabs)
  • 5.2.2 Bayhill Therapeutics Vacine (BHT-3009)
  • 5.2.3 BHT-3009 Non-broad-based immunosuppressant mechanism
  • 5.2.4 BioMS (MBP 8298) synthetic fragment Phase II study shows delayed progression of MS for 5 years
• Table 5.2.MS phase III pipeline
• Table 5.3. MS phase II pipeline
• Table 5.4. MS phase I pipeline

Chapter 6. Children with MS

• 6.1 Paediatric MS
  • 6.1.1Disease course of Paediatric MS
  • 6.1.2Progression of Paediatric MS
  • 6.1.3Challenges in diagnosis of paediatric MS
  • 6.1.4Treatment options for Paediatric MS
• Table 6.1 Paediatric MS Dosage of Disease Modifying Drugs

Chapter 7. Multiple Sclerosis Disease Modifying Drugs Market Analysis in the Seven Major Markets

• 7.1 US Market Analysis
  • Chart 7.1 US Market Growth Rate 2002-2003
  • Chart 7.2 US Health Budget Allocation in comparison to other Regions
  • Chart 7.3. Population With and Without Health Insurance Coverage in the US
  • Chart 7.4. Split of Health Insurance Providers in the US
  • 7.1.2 US Expenditure on Pharmaceutical products
    • Chart 7.5.US Pharmaceutical Market Revenue 2005-2006
  • 7.1.3 Overview of Approved MS Therapeutics in US Market
    • Chart 7.6. US one year cost to treat MS patients with the disease modifying drugs
  • 7.1.4 US Major MS Therapeutics
    • 7.1.5.1 Biogen Idec' s Avonex
    • 7.1.5.2Biogen Idec Future targets for Avonex
    • 7.1.5.3Teva and Aventis (Sanofi-Aventis) Copaxane
    • 7.1.5.4 Merck Serono' s Rebif
    • 7.1.5.5 Bayer Schering Betaseron
    • 7.1.5.6 Biogen Idec and Elan' s Tysabri
    • 7.1.5.7 Antineoplastic Drugs (Relapse-Remitting & Secondary progressive)
    • 7.1.5.8Cancer Drug, Novantrone (Mixonatrone) Benefits MS Sufferers
    • 7.1.5.9 US MS Market Revenue Forecast 2007-2012
      • Table 7.1.US MS Disease Modifying Drugs Revenues ($bn), Forecast 2007-2012, 2017 & 2022
      • Chart 7.7.US MS Disease Modifying Drugs Revenues ($bn) Forecast 2007-2012, 2017 & 2022
        • Chart 7.8.1 US Avonex Combined Revenues ($m), 2003-2006
        • Chart 7.8.2 US Avonex Split Revenues ($m), 2003-2006
        • Chart 7.8.3 US Copaxone Combined Revenues ($m), 2003-2006
        • Chart 7.8.4 US Copaxone split Revenues ($m), 2003-2006
        • Chart 7.8.5 US Rebif Combined Revenues ($m), 2003-2006
        • Chart 7.8.6US Rebif split Revenues ($m), 2003-2006
        • Chart 7.8.7 US Befaseron Combined Revenues ($m), 2003-2006
        • Chart 7.8.8US Befaseron split Revenues ($m) 2003-2006
        • Chart 7.8.9 Tysabri split Revenues ($m), 2006
        • Chart 7.8.10US Novantrone combined Revenues ($m) 2003-2006
        • Chart 7.8.11 US Novantrone split Revenues ($m) 2003-2006
• 7.2. US MS Market Drivers and Restraints
  • 7.2.1 Market Drivers
  • 7.2.2 Market Restraints
• 7.2Japan Pharmaceutical Market Outlook
  • Chart 7.12 Japan Pharmaceutical Revenues ($bn), 2004-2006
• 7.3 Japan' s Healthcare System
  • 7.3.1 Medical Expenditure in Japan
    • Chart 7.13 Japan Medical Expenditure 1990s (JPY Trillions)
  • 7.3.2 Japan Healthcare Strategic Reform
  • 7.3.3 Strategic long-term care insurance care reforms
  • 7.3.4 Japan Pharmaceutical Market Analysis
  • 7.3.5 Overview of Approved MS Therapeutics in Japanese Market
    • 7.3.6.1 MS Product in the Japanese Market
      • Chart 7.14 Revenues of Three Major MS Drugs in Japan, 2006
    • 7.3.6.2 Biogen Idec' s Avonex Japanese Market Analysis
      • Chart 7.15 Avonex Split Revenues ($m) in Japan,2006
    • 7.3.6.3 Bayer Schering' s Betaseron Japanese Market Analysis
      • Chart 7.16 Betaferon Combined Revenues ($m) in Japan 2003-2006
      • Chart 7.17Betaferon Split Revenues ($m) in Japan 2003-2006
    • 7.3.6.4 Merck Serono' s Novantrone Japanese Market Analysis
      • Chart 7.18Novantrone Combined Revenues ($m) in Japan 2003-2006
      • Chart 7.19 Novantrone split Revenues ($m) in Japan 2003-2006
    • 7.3.6.5Japan MS Market Revenue Forecast 2007-2012,2017 & 2022
      • Table 7.2 Japan MS Major Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
      • Chart 7.20 Japan MS Major Drugs Revenue ($m) Forecast 2007-2012
• 7.4 Market Drivers and Restraints
  • 7.4.1 Market Drivers
  • 7.4.2 Market Restraints
• 7.5 France Pharmaceutical Market Outlook
  • Chart 7.21 France' s Pharmaceutical Market Revenues ($bn) 2002-2006
  • 7.5.1 Healthcare System
  • 7.5.2 France' s Health and Medical Expenditure
  • 7.5.3 Major MS Product in the French Market
    • Chart 7.22 Major MS disease modifying drugs in France
    • 7.5.4.1 Biogen Idec' s Avonex Market Analysis in France
      • Chart 7.23 Biogen Idec combined Revenue ($m), 2003-2006
      • Chart 7.24 Biogen Idec Avonex Split Revenue ($m), 2003-2006
    • 7.5.4.2 Merck Serono' s Rebif Market Analysis in France
      • Chart 7.25 Rebif combined Revenue ($m), 2003-2006
      • Chart 7.26 Rebif Split Revenue ($m), 2003-2006
    • 7.5.4.3 Bayer Schering' s Betaferon Market Analysis in France
      • Chart 7.27 Betaferon combined Revenues ($m), 2003-2006
      • Chart 7.28 Betaferon Split Revenues ($m), 2003-2006
    • 7.5.4.4 Teva and Sanofi-Aventis' Copaxone Market Analysis in France
      • Chart 7.29 Copaxone combined Revenue ($m) 2003-2006
      • Chart 7.30 Copaxone split Revenue ($m) 2003-2006
    • 7.5.4.5 Merck Serono' s Novantrone Market Analysis in France
      • Chart 7.31 Serono' s declining Novantrone Revenue ($m), 2003-2006
• 7.6 Tysabri to reach the French Market
• 7.7 France' s MS Market Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Chart 7.32 France Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Table 7.3 France Disease Modifying Drugs Revenues ($m), Forecast 2007-2012, 2017 & 2022
• 7.8 France' s MS Market Drivers and Restraints
  • 7.8.1 Market Drivers
  • 7.8.2 Market Restraints
• 7.9 Germany Pharmaceutical Outlook
  • Chart 7.33 Germany' s Pharmaceutical Revenues ($bn), 2002-2007
  • 7.9.1 Germany Healthcare System
  • 7.9.2 Pharmaceutical Sector Reforms
  • 7.9.3 Major MS Product in the German Market
    • Chart 7.34Major MS disease modifying drugs in Germany
    • 7.9.3.1 Merck Serono' s Rebif leading disease modifying drug in Germany 2006
      • Chart 7.35 Rebif' s Combined Revenues ($m), 2003-2006
      • Chart 7.36 Rebif' s Split Revenues ($m), 2003-2006
    • 7.9.3.2 Bayer Schering Betaferon German Market Analysis
      • Chart 7.37 Betaferon Combined Revenues ($m), 2003-2006
      • Chart 7.38 Betaferon Split Revenues ($m),.2003-2006
    • 7.9.3.3 Biogen Idec' s Avonex Market Analysis in Germany
      • Chart 7.39 Avonex Combined Revenues ($m), 2003-2006
      • Chart 7.40 Avonex Revenues ($m), 2003-2006
    • 7.9.3.4 Teva and Sanofi-Aventis Copaxone Market Analysis in Germany
      • Chart 7.41 Copaxone Combined Revenues ($m), 2003-2006
      • Chart 7.42 Copaxone Split Revenues ($m), 2003-2006
    • 7.9.3.5 Serono' s Novantrone Market Analysis in Germany
      • Chart 7.43 Novantrone Combined Revenues ($m), 2003-2006
    • 7.9.3.6 Biogen Idec and Elan' s Tysabri Market Analysis in Germany
      • Chart 7.41 Tysabri Split Revenues ($m), 2006
• 7.10 Germany MS Market Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Table 7.4 Germany Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Chart 7.45 Germany Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
• 7.11 Germany MS Market Drivers and Restraints
  • 7.11.1 Market Drivers
  • 7.11.2 Market Restraints
• 7.12 UK Pharmaceutical Outlook
  • Chart 7.46 UK Global Pharmaceutical Revenues ($bn), 2002-2006
  • 7.12.1 UK Healthcare system
  • 7.12.2 UK NHS and Department of Health
  • 7.12.3 NHS and Private Healthcare
  • 7.12.4 UK Healthcare Insurance Policies
  • 7.12.5 Current NHS Prescription Volumes
  • 7.12.6 Dominance of Generic Market
  • 7.12.7 Major MS Product in the UK market
    • Chart 7.47 UK Major MS Disease Modifying Drugs
    • 7.12.7.1 Teva and Sanofi-Aventis' s Copaxone leading Disease modifying drug in the UK in 2006
      • Chart 7.48 Copaxone Combined Revenues ($m), 2003-2006
      • Chart 7.49 Copaxone Split Revenues ($m), 2003-2006
    • 7.12.7.2 Merck Serono' s Rebif UK market analysis
      • Chart 7.50 Rebif Combined Revenues ($m), 2003-2006
      • Chart 7.51 Rebif Split Revenues ($m), 2003-2006
    • 7.12.7.3 Biogen Idec Avonex UK market Growth
      • Chart 7.52 Avonex Combined Revenues ($m), 2003-2006
      • Chart 7.53 Avonex Split Revenues ($m), 2003-2006
    • 7.12.7.4 Bayer Schering Betaferon UK market Growth
      • Chart 7.54 Betaferon Combined Revenues ($m), 2003-2006
    • 7.12.7.5 Serono' s Novantrone UK Market
      • Chart 7.56 Novantrone Combined Revenues ($m), 2003-2006
• 7.13. NICE approves Biogen Idec and Elan' s Tysabri in the UK
• 7.14. UK Sector to grow and dominate MS Market in Europe
• 7.15.UK MS Market Revenues ($m) Forecast 2007-2012, 2017 & 2022
  • Table 7.5 UK Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Chart 7.57 UK Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
• 7.16 UK MS Market Drivers and Restraints
  • 7.16.1 Market Drivers
  • 7.16.2 Market Restraints
• 7.17 Italy Pharmaceutical Outlook
  • Chart 7.58 Italy' s Pharmaceutical Revenues ($bn), 2004-2006
  • 7.17.1 Italy' s Healthcare System and Reforms
  • 7.17.2 The Major MS Product in the Italian market
  • Chart 7.59 Italy' s Major MS Disease Modifying Drugs
    • 7.17.2.1 Merck Serono' s Rebif leading beta interferon for MS in Italy
      • Chart 7.60 Rebif Combined Revenues ($m),2003-2006
      • Chart 7.61 Rebif Split Revenues ($m),2003-2006 Avonex Italy Market Analysis
    • 7.17.2.2 Biogen Idec' s Avonex Italy Market Analysis
      • Chart 7.62 Avonex Combined Revenues ($m),2003-2006
      • Chart 7.63 Avonex Split Revenues ($m),2003-2006
    • 7.17.2.3 Bayer Schering Betaseron Italy Market Analysis
      • Chart 7.64 Betaferon Total Revenues ($m),2003-2006
    • 7.17.2.4 Teva and Sanofi-Aventis' Copaxone Italy Market Analysis
      • Chart 7.65 Copaxone Combined Revenues ($m), 2003-2006
      • Chart 7.66 Copaxone Split Revenues ($m), 2003-2006
    • 7.17.2.5 Serono' s Novantrone Italy Market Analysis
      • Chart 7.67 Novantrone Total Revenues ($m), 2003-2006
• 7.18 Italy MS Market Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Table 7.6 Italy Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Chart 7.68 Italy Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
• 7.19 Italy MS Market Drivers and Restraints
  • 7.19.1 Market Drivers
  • 7.19.2Market Restraints
• 7.20 Spain' s Pharmaceutical Outlook
  • Chart 7.69 Spain Pharmaceutical Revenues ($bn), 2002-2006
  • 7.20.1 The Major MS Product in the Spanish market
    • Chart 7.70 Major MS Disease Modifying Drugs in Spain
    • 7.20.1.1 Merck Serono' s Rebif leading MS product in Spain
      • Chart 7.71 Rebif Total Revenues ($m), 2003-2006
    • 7.19.2.2 Biogen Idec' s Avonex Spainish Market Analysis
      • Chart 7.72 Avonex Total Revenues ($m), 2003-2006
    • 7.20.1.3 Bayer Schering Betaferon Spain Market Analysis
      • Chart 7.73 Betaferon Total Revenues ($m), 2003-2006
    • 7.20.1.4Teva and Sanofi-Aventis Copaxone Spain Market Analysis
      • Chart 7.74 Copaxone Total Revenues ($m), 2003-2006
    • 7.20.1.5 Serono' s Novantone Spain Market analysis
      • Chart 7.75 Novantrone Total Revenues ($m), 2003-2006
• 7.21 Spain MS Market Revenues ($m) Forecast, 2007-2012, 2017 & 2022
  • Table 7.7 Spain Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
  • Chart 7.76 Spain Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
• 7.22 Spain MS Market Drivers and Restraints
  • 7.22.1 Market Drivers
  • 7.22.2 Market Restraints

Chapter 8. Conclusion

• Table 8.1 Leading Companies with Oral MS Products late stage phase III studies to reach market by 2010

• Organisations mentioned
• Abbot Laboratories
• Accentia Biopharma
• Active Biotech
• American Pharmaceutical Partners
• Antisense Therapeutics
• Artielle ImmunoTherapeutics
• AstraZeneca
• Bayer Schering
• Bayhill Therapeutics
• Bedford Labs
• Berlex Laboratories
• BioCryst
• Biogen Idec
• BioMS
• Bristol Myers Squib
• Caisse Nationale d' Assurance Maladie des Travailleurs Salariés (CNAMTS) C-Bio Cell Therapeutics ChemoCentryx Comite Economique des Sante (CEPS) Couverture Maladie Universelle (CMU) Dartmouth Dartmouth-Hitchcock Eisai Elan Corp Farmacija Gemacbio Genentech Genmab Genzyme GlaxoSmithKlien GW Pharmaceutical Hemispherx Biopharma
• Hoffmann- La Roche
• Hospices Civils de Lyon
• Incyte
• Janssen-Cilag
• Japanese Ministry of Health and Welfare
• LTKfarma
• Mayne Pharma
• Medarex
• Medicinova
• Merck Serono
• Merrimack
• Millennium Pharma
• Mitsubishi Pharma Corporation
• Mutualité Sociale Agricole (MSA)
• Neuren
• Neurology Research Group - Plymouth
• Novartis
• NovImmune
• Nutra Pharma
• Orchestra Therapeutics
• Otsuka
• Pepgen
• Pfizer
• Pipex
• Protein Design Labs
• ReceptoPharm
• Régime Social des Indépendants (RSI)
• Roche
• S. Andrea Hospital
• Sanofi-Aventis
• Seattle Genetics
• Sicor
• Stanford and Pacific Pharmaceuticals
• Stem Cell Therapeutics
• Takeda Pharma
• Tanabe
• Teva
• UCB
• UK National Institute of Clinical Excellence (NICE)
• University Medical Centre Groningen
• University of Cambridge
• University of Milano-Bicocca
• University of San Fransico (UCSF)
• University of Wisconsin
• World Health Organisation (WHO)
• Wyeth